Wenqing Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wenqing Xu has a total of 325 co-authors. Here are the top co-authors by number of shared publications:
Zhizhi Wang
School of Life Science and Technology, ShanghaiTech University, Shanghai, China
16 shared publicationsDavid Kimelman
Departments of Biochemistry, University of Washington, Seattle, WA 98195, USA
7 shared publications- Zhizhi Wang
School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China
7 shared publications - Xiao-Xue Yan
National Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
6 shared publications Yi Xing
Department of Biological Structure, University of Washington School of Medicine, Seattle, WA 98195, USA
6 shared publications- Uhn-Soo Cho
Department of Biological Chemistry, University of Michigan, Ann Arbor, Michigan 48109, USA
5 shared publications
Latest Publications
- 26 May 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 368, 152719
Disruption of BCL9-β-catenin interaction by de novo designed miniproteins inhibits oncogenic signaling
- 26 May 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 368, 152719
Disruption of BCL9-β-catenin interaction by de novo designed miniproteins inhibits oncogenic signaling
- Open Access
- 9 April 2026
- Published by Elsevier in Trends in Biotechnology
- Vol. 44 (9) , 2646-2678
Rationally designed light-inducible RNA-releasing protein for translational regulation and optogenetic control of gene therapies
- 9 April 2026
- Published by Elsevier in Trends in Biotechnology
- Vol. 44 (9) , 2646-2678
Open AccessRationally designed light-inducible RNA-releasing protein for translational regulation and optogenetic control of gene therapies
- Open Access
- 24 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Cryo-EM structures of light chain fibrils from abdominal fat biopsies of multiple myeloma patients
Multiple myeloma (MM) is a hematological malignancy characterized by the abnormal proliferation of plasma cells in the bone marrow and is closely associated with systemic light chain amyloidosis (AL), a disease triggered by the amyloid aggregation of antibody light chain (LC). High-resolution structures of amyloid LC fibrils from MM patients remain largely unexplored. Here, we extracted LC amyloid fibrils directly from abdominal fat biopsies of two living MM patients. Using cryo-electron microscopy (cryo-EM), we further determined the structures of three distinct LC fibril morphologies, which differ significantly from previously reported fibril structures derived from AL amyloidosis patients. Structural comparisons and computational analyses suggested distinct LC fibrillation mechanisms in MM compared to AL amyloidosis, highlighting a potential role of elevated protein concentration in driving LC aggregation in MM. These findings provide essential molecular insights into LC fibril formation in MM and offer a structural foundation for biological diagnosis of living MM patients based on accessible abdominal fat biopsy samples.
- 24 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessCryo-EM structures of light chain fibrils from abdominal fat biopsies of multiple myeloma patients
Multiple myeloma (MM) is a hematological malignancy characterized by the abnormal proliferation of plasma cells in the bone marrow and is closely associated with systemic light chain amyloidosis (AL), a disease triggered by the amyloid aggregation of antibody light chain (LC). High-resolution structures of amyloid LC fibrils from MM patients remain largely unexplored. Here, we extracted LC amyloid fibrils directly from abdominal fat biopsies of two living MM patients. Using cryo-electron microscopy (cryo-EM), we further determined the structures of three distinct LC fibril morphologies, which differ significantly from previously reported fibril structures derived from AL amyloidosis patients. Structural comparisons and computational analyses suggested distinct LC fibrillation mechanisms in MM compared to AL amyloidosis, highlighting a potential role of elevated protein concentration in driving LC aggregation in MM. These findings provide essential molecular insights into LC fibril formation in MM and offer a structural foundation for biological diagnosis of living MM patients based on accessible abdominal fat biopsy samples.
- Open Access
- 3 September 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (36)
De novo design of protein binders to stabilize monomeric TDP-43 and inhibit its pathological aggregation
Pathological aggregation of transactive response DNA binding protein of 43 kDa (TDP-43), primarily driven by its low-complexity domain, is closely associated with various neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Despite the therapeutic potential of preventing TDP-43 aggregation, no effective small molecule or biomacromolecule therapeutics have been successfully developed so far. Here, we introduce a protein design strategy that yields de novo designed proteins capable of stabilizing the key amyloidogenic region of TDP-43 in its native helical conformation with nanomolar binding affinity. The binding mechanism was further characterized by the NMR and mutagenesis study. More importantly, we demonstrated that our designed protein binders efficiently reduced TDP-43 amyloid aggregation both in vitro and in cells. Our work provides a strategy for designing protein stabilizer of the native conformation of pathological proteins for preventing its amyloid aggregation, shedding light on the development of potential therapeutic approaches for ALS, FTLD, and other protein aggregation-associated diseases.
- 3 September 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (36)
Open AccessDe novo design of protein binders to stabilize monomeric TDP-43 and inhibit its pathological aggregation
Pathological aggregation of transactive response DNA binding protein of 43 kDa (TDP-43), primarily driven by its low-complexity domain, is closely associated with various neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Despite the therapeutic potential of preventing TDP-43 aggregation, no effective small molecule or biomacromolecule therapeutics have been successfully developed so far. Here, we introduce a protein design strategy that yields de novo designed proteins capable of stabilizing the key amyloidogenic region of TDP-43 in its native helical conformation with nanomolar binding affinity. The binding mechanism was further characterized by the NMR and mutagenesis study. More importantly, we demonstrated that our designed protein binders efficiently reduced TDP-43 amyloid aggregation both in vitro and in cells. Our work provides a strategy for designing protein stabilizer of the native conformation of pathological proteins for preventing its amyloid aggregation, shedding light on the development of potential therapeutic approaches for ALS, FTLD, and other protein aggregation-associated diseases.
- Open Access
- 20 August 2025
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 17 (1) , 83-88
Structure-based engineering of the midnolin-proteasome pathway for targeted protein degradation
- 20 August 2025
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 17 (1) , 83-88
Open AccessStructure-based engineering of the midnolin-proteasome pathway for targeted protein degradation
- Open Access
- 9 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 7368
Design of Ig-like binders targeting α-synuclein fibril for mitigating its pathological activities
Parkinson's disease (PD) is characterized by the accumulation and spread of pathological α-synuclein (α-syn) fibrils, which contribute to neuroinflammation and neurodegeneration. Here we show that two immunoglobulin-like (Ig-like) domains derived from α-syn receptors, the D1 domain of lymphocyte-activation gene 3 (L3D1) and the V domain of advanced glycation end-products (vRAGE), effectively block cell surface binding of α-syn fibrils, suppress fibrils-induced neuronal α-syn aggregation, and reduce inflammatory responses in microglia. Building on this, we identified two additional Ig-like binders, the D1 domain of cluster of differentiation 4 (CD4 D1) and the D1 domain of chimeric antigen receptor (CAR D1), that target the C-terminal region of α-syn fibrils and mitigate fibrils-induced pathological activities. A structure-guided mutant, CAR D1_Mut, exhibits enhanced binding affinity and functional efficacy. These findings highlight the potential of Ig-like binders as molecular tools to interfere with pathological α-syn interactions.
- 9 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 7368
Open AccessDesign of Ig-like binders targeting α-synuclein fibril for mitigating its pathological activities
Parkinson's disease (PD) is characterized by the accumulation and spread of pathological α-synuclein (α-syn) fibrils, which contribute to neuroinflammation and neurodegeneration. Here we show that two immunoglobulin-like (Ig-like) domains derived from α-syn receptors, the D1 domain of lymphocyte-activation gene 3 (L3D1) and the V domain of advanced glycation end-products (vRAGE), effectively block cell surface binding of α-syn fibrils, suppress fibrils-induced neuronal α-syn aggregation, and reduce inflammatory responses in microglia. Building on this, we identified two additional Ig-like binders, the D1 domain of cluster of differentiation 4 (CD4 D1) and the D1 domain of chimeric antigen receptor (CAR D1), that target the C-terminal region of α-syn fibrils and mitigate fibrils-induced pathological activities. A structure-guided mutant, CAR D1_Mut, exhibits enhanced binding affinity and functional efficacy. These findings highlight the potential of Ig-like binders as molecular tools to interfere with pathological α-syn interactions.
- 2 July 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 319 (Pt 4) , 145700
Development of nanobody-based PROTAC (NbTAC) for ROR1 degradation by RNF149
- 2 July 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 319 (Pt 4) , 145700
Development of nanobody-based PROTAC (NbTAC) for ROR1 degradation by RNF149
- Open Access
A potent and broad‐spectrum neutralizing nanobody for SARS‐CoV‐2 viruses, including all major Omicron strains
SARS‐CoV‐2 viruses are highly transmissible and immune evasive. It is critical to develop broad‐spectrum prophylactic and therapeutic antibodies for potential future pandemics. Here, we used the phage display method to discover nanobodies (Nbs) for neutralizing SARS‐CoV‐2 viruses especially Omicron strains. The leading nanobody (Nb), namely, Nb4, with excellent physicochemical properties, can neutralize Delta and Omicron subtypes, including BA.1, BA.1.1 (BA.1 + R346K), BA.2, BA.5, BQ.1, and XBB.1. The crystal structure of Nb4 in complex with the receptor‐binding domain (RBD) of BA.1 Spike protein reveals that Nb4 interacts with an epitope on the RBD overlapping with the receptor‐binding motif, and thus competes with angiotensin‐converting enzyme 2 (ACE2) binding. Nb4 is expected to be effective for neutralizing most recent Omicron variants, since the epitopes are evolutionarily conserved among them. Indeed, trivalent Nb4 interacts with the XBB1.5 Spike protein with low nM affinity and competes for ACE2 binding. Prophylactic and therapeutic experiments in mice indicated that Nb4 could reduce the Omicron virus loads in the lung. In particular, in prophylactic experiments, intranasal administration of multivalent Nb4 completely protected mice from Omicron infection. Taken together, these results demonstrated that Nb4 could serve as a potent and broad‐spectrum prophylactic and therapeutic Nb for COVID‐19.
Open AccessA potent and broad‐spectrum neutralizing nanobody for SARS‐CoV‐2 viruses, including all major Omicron strains
SARS‐CoV‐2 viruses are highly transmissible and immune evasive. It is critical to develop broad‐spectrum prophylactic and therapeutic antibodies for potential future pandemics. Here, we used the phage display method to discover nanobodies (Nbs) for neutralizing SARS‐CoV‐2 viruses especially Omicron strains. The leading nanobody (Nb), namely, Nb4, with excellent physicochemical properties, can neutralize Delta and Omicron subtypes, including BA.1, BA.1.1 (BA.1 + R346K), BA.2, BA.5, BQ.1, and XBB.1. The crystal structure of Nb4 in complex with the receptor‐binding domain (RBD) of BA.1 Spike protein reveals that Nb4 interacts with an epitope on the RBD overlapping with the receptor‐binding motif, and thus competes with angiotensin‐converting enzyme 2 (ACE2) binding. Nb4 is expected to be effective for neutralizing most recent Omicron variants, since the epitopes are evolutionarily conserved among them. Indeed, trivalent Nb4 interacts with the XBB1.5 Spike protein with low nM affinity and competes for ACE2 binding. Prophylactic and therapeutic experiments in mice indicated that Nb4 could reduce the Omicron virus loads in the lung. In particular, in prophylactic experiments, intranasal administration of multivalent Nb4 completely protected mice from Omicron infection. Taken together, these results demonstrated that Nb4 could serve as a potent and broad‐spectrum prophylactic and therapeutic Nb for COVID‐19.